8-K
filed April 3, 2025, 7:59 PM ET
CIK 0001444380
M&A
confidence high
sentiment neutral
materiality 1.00
NEVRO CORP: M&A transaction — Completed acquisition by Globus Medical for $5.85/share; Nevro now wholly owned subsidiary
NEVRO CORP
- Holders of Nevro shares received $5.85 per share in cash; stock options and RSUs cancelled for cash.
- On April 1, Nevro repaid ~$190M principal plus ~$2.61M accrued interest on 2.75% Convertible Senior Notes.
- Nevro terminated its $200M Credit Agreement, paying ~$227.1M including principal, interest, and fees.
- All Nevro directors resigned; Globus designees installed. Nevro requested delisting from NYSE and plans to deregister.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin O’Boyle resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Karen N. Prange resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sri Kosaraju resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin Thornal resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shawn T. McCormick resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael DeMane resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kirt Karros resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
D. Keith Grossman resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Susan Siegel resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Elizabeth Weatherman resigned as Director at NEVRO CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Keith Pfeil was appointed as Director at NEVRO CORP.
- Action
- appointed
- Role
- Director
Exact text from the filing
each of Daniel Scavilla and Keith Pfeil, the directors of Merger Sub immediately prior to the Effective Time, became the directors of Nevro.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Scavilla was appointed as Director at NEVRO CORP.
- Action
- appointed
- Role
- Director
Exact text from the filing
each of Daniel Scavilla and Keith Pfeil, the directors of Merger Sub immediately prior to the Effective Time, became the directors of Nevro.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
NEVRO CORP: Certificate of incorporation amended and restated in its entirety as of the Effective Time pursuant to Merger Agreement.
- Change
- charter amendment
Exact text from the filing
the certificate of incorporation of Nevro and the bylaws of Nevro, each as in effect immediately prior to the Effective Time, were each amended and restated in their entirety
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
NEVRO CORP: Bylaws amended and restated in their entirety as of the Effective Time pursuant to Merger Agreement.
- Change
- bylaw amendment
Exact text from the filing
the certificate of incorporation of Nevro and the bylaws of Nevro, each as in effect immediately prior to the Effective Time, were each amended and restated in their entirety
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
NEVRO CORP underwent a change of control involving Globus Medical, Inc. for $5.85 per Nevro Share in cash (closed 2025-04-03).
- Action
- change of control
- Counterparty
- Globus Medical, Inc.
- Consideration
- $5.85 per Nevro Share in cash
- Closing
- 2025-04-03
Exact text from the filing
or Nevro or by any direct or indirect wholly owned subsidiary of Globus, Merger Sub or Nevro was canceled and extinguished and automatically converted into the right to receive $5.85 per Nevro Share in cash (the “Merger Consideration”), without interest and subject to any applicable withholding taxes. In addition, effective as of immediately prior to the
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.